You are here
Disease modifying therapies
Interview with Patricia K. Coyle: Improvement in patient-reported outcomes with Teriflunomide: Week 24 interim results from the US Cohort of the Teri-PRO Phase 4 StudyProfessor Coyle explained that Teri-PO is a global phase IV post-marketing study. This is a real world analysis of patients...
Interview with Ludwig Kappos: Effect of daclizumab HYP vs. intramuscular interferon beta-1a on no evidence of disease activity in patients with relapsing-remitting MS: analysis of the DECIDE StudyProfessor Kappos and his colleagues conducted a randomized, double-blind, active-controlled, international phase 3 study (the DECIDE study] involving 1841 patients...
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims AnalysisJ Manag Care Spec Pharm. 2015 Aug;21(8):650-60.
- J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1202-7. doi: 10.1136/jnnp-2014-310024. Epub 2015 Sep 15.
Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction
Andrea Zimmer, Cornelia Bläuer, Michael Coslovsky, Ludwig Kappos, Tobias Derfuss
Multiple Sclerosis and Related Disorders, Volume 4, Issue 5, September 2015, Pages 444 - 450
- Merck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
- In the first 2 years of the study, patients with RRMS (relapsing remitting multiple sclerosis) were given randomised treatment with...
- Professor Giovannoni described the initiative "Brain Health: Time Matters in Multiple Sclerosis". This was because patients suffer delays in accessing...
- Dr. Prat discussed the selection of drugs for the treatment of multiple sclerosis.Therapy choices must be based on adequate disease control, safety, tolerability, adherence, safety monitoring and concomitant medication.
- According to Professor Freedman, treatment of multiple sclerosis should delay or prevent the accumulation of permanent disability and should be evaluated over a prolonged time frame, with an absolute minimum of 2 years of therapy.